Articles published by Gossamer Bio, Inc.
![](https://mms.businesswire.com/media/20240812706587/en/818570/22/GossamerBio-Logo.jpg)
Gossamer Bio Announces Second Quarter 2024 Financial Results and Provides Business Update
August 12, 2024
From Gossamer Bio, Inc.
Via Business Wire
Tickers
GOSS
![](https://mms.businesswire.com/media/20240607352857/en/818570/22/GossamerBio-Logo.jpg)
![](https://mms.businesswire.com/media/20240514616477/en/818570/22/GossamerBio-Logo.jpg)
![](https://mms.businesswire.com/media/20240510801953/en/818570/22/GossamerBio-Logo.jpg)
![](https://mms.businesswire.com/media/20240507376644/en/818570/22/GossamerBio-Logo.jpg)
Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update
May 07, 2024
From Gossamer Bio, Inc.
Via Business Wire
Tickers
GOSS
![](https://mms.businesswire.com/media/20240506306603/en/818570/22/GossamerBio-Logo.jpg)
![](https://mms.businesswire.com/media/20240503252709/en/818570/22/GossamerBio-Logo.jpg)
Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine
May 03, 2024
From Gossamer Bio, Inc.
Via Business Wire
Tickers
GOSS
![](https://mms.businesswire.com/media/20240312927389/en/818570/22/GossamerBio-Logo.jpg)
Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors
March 12, 2024
From Gossamer Bio, Inc.
Via Business Wire
Tickers
GOSS
![](https://mms.businesswire.com/media/20240305623826/en/818570/22/GossamerBio-Logo.jpg)
Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
March 05, 2024
From Gossamer Bio, Inc.
Via Business Wire
Tickers
GOSS
![](https://mms.businesswire.com/media/20240108831811/en/818570/22/GossamerBio-Logo.jpg)
![](https://mms.businesswire.com/media/20231213371661/en/818570/22/GossamerBio-Logo.jpg)
Gossamer Bio to Host Webcast to Discuss Latest Seralutinib Open-Label Extension Data on December 18, 2023
December 13, 2023
From Gossamer Bio, Inc.
Via Business Wire
Tickers
GOSS
![](https://mms.businesswire.com/media/20231205707079/en/818570/22/GossamerBio-Logo.jpg)
![](https://mms.businesswire.com/media/20231205329570/en/818570/22/GossamerBio-Logo.jpg)
Gossamer Bio Appoints Bob Smith as Chief Commercial Officer
December 05, 2023
From Gossamer Bio, Inc.
Via Business Wire
Tickers
GOSS
![](https://mms.businesswire.com/media/20231129247724/en/818570/22/GossamerBio-Logo.jpg)
Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of Directors
November 29, 2023
From Gossamer Bio, Inc.
Via Business Wire
Tickers
GOSS
![](https://mms.businesswire.com/media/20231109622240/en/818570/22/GossamerBio-Logo.jpg)
Gossamer Bio Announces Third Quarter 2023 Financial Results and Provides Business Update
November 09, 2023
From Gossamer Bio, Inc.
Via Business Wire
Tickers
GOSS
![](https://mms.businesswire.com/media/20231003478160/en/818570/22/GossamerBio-Logo.jpg)
![](https://mms.businesswire.com/media/20230907147954/en/818570/22/GossamerBio-Logo.jpg)
Gossamer Bio to Present Results of TORREY FRI Sub-Study at the European Respiratory Society International Congress 2023
September 07, 2023
From Gossamer Bio, Inc.
Via Business Wire
Tickers
GOSS
![](https://mms.businesswire.com/media/20230808193999/en/818570/22/GossamerBio-Logo.jpg)
Gossamer Bio Announces Second Quarter 2023 Financial Results and Provides Business Update
August 08, 2023
From Gossamer Bio, Inc.
Via Business Wire
Tickers
GOSS
![](https://mms.businesswire.com/media/20230724758177/en/818570/22/GossamerBio-Logo.jpg)
![](https://mms.businesswire.com/media/20230720022834/en/818570/22/GossamerBio-Logo.jpg)
![](https://mms.businesswire.com/media/20230518005332/en/818570/22/GossamerBio-Logo.jpg)
![](https://mms.businesswire.com/media/20230509005943/en/818570/22/GossamerBio-Logo.jpg)
Gossamer Bio Announces First Quarter 2023 Financial Results and Provides Business Update
May 09, 2023
From Gossamer Bio, Inc.
Via Business Wire
Tickers
GOSS
![](https://mms.businesswire.com/media/20230317005063/en/818570/22/GossamerBio-Logo.jpg)
Gossamer Bio Announces Fourth Quarter and Full-Year 2022 Financial Results and Provides Business Update
March 17, 2023
From Gossamer Bio, Inc.
Via Business Wire
Tickers
GOSS
![](https://mms.businesswire.com/media/20221206005388/en/818570/5/GossamerBio-Logo.jpg)
Gossamer Bio Announces Seralutinib Meets Primary Endpoint in Phase 2 TORREY Study in PAH
December 06, 2022
From Gossamer Bio, Inc.
Via Business Wire
Tickers
GOSS
![](https://mms.businesswire.com/media/20221103006082/en/818570/5/GossamerBio-Logo.jpg)
Gossamer Bio Announces Third Quarter 2022 Financial Results and Provides Business Update
November 03, 2022
From Gossamer Bio, Inc.
Via Business Wire
Tickers
GOSS
![](https://mms.businesswire.com/media/20220809005148/en/818570/5/GossamerBio-Logo.jpg)
Gossamer Bio Announces Second Quarter 2022 Financial Results and Provides Business Update
August 09, 2022
From Gossamer Bio, Inc.
Via Business Wire
Tickers
GOSS
![](https://mms.businesswire.com/media/20220713005302/en/818570/5/GossamerBio-Logo.jpg)
![](https://mms.businesswire.com/media/20220609005043/en/790332/5/GossamerBio-Logo_%281%29.jpg)
![](https://mms.businesswire.com/media/20220510005665/en/818570/5/GossamerBio-Logo.jpg)
Gossamer Bio Announces First Quarter 2022 Financial Results and Provides Business Update
May 10, 2022
From Gossamer Bio, Inc.
Via Business Wire
Tickers
GOSS
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.